The market for government-approved medication targeting long-term weight reduction and maintenance is expanding. On Wednesday, the U.S. Food and Drug Administration approved Zepbound, which is made by Eli Lilly and Company and intended for use by adults with obesity or those suffering from a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. The medication, which is intended to be combined with a reduced-calorie diet and increased physical activity, is expected to available by the end of the year.

Tirzepatide, the active ingredient in Zepbound for weight loss, is already approved under the trade name Mounjaro for use along with diet and exercise to help improve glucose levels in adults with type 2 diabetes mellitus.

"Obesity is a chronic disease that can result in serious health complications, including heart disease, stroke, and diabetes. Despite our knowledge of obesity as a treatable, chronic disease, people living with obesity still face many challenges in their health and weight management journey," Joe Nadglowski, president and chief executive officer of the Obesity Action Coalition, said in a statement issued by Lilly. "New treatment options bring hope to the many people with obesity who struggle with this disease and are seeking better options for weight management."